These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 31920340)

  • 1. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.
    Chen Q; Zhang ZH; Wang S; Lang JH
    Onco Targets Ther; 2019; 12():11517-11530. PubMed ID: 31920340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy.
    Marrugo-Ramírez J; Mir M; Samitier J
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30248975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.
    Jamieson A; McConechy MK; Lum A; Senz J; Dowhy T; Huntsman DG; McAlpine JN
    J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38909641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
    Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
    Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
    Cheng X; Zhang L; Chen Y; Qing C
    J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer.
    Casas-Arozamena C; Díaz E; Moiola CP; Alonso-Alconada L; Ferreirós A; Abalo A; Gil CL; Oltra SS; de Santiago J; Cabrera S; Sampayo V; Bouso M; Arias E; Cueva J; Colas E; Vilar A; Gil-Moreno A; Abal M; Moreno-Bueno G; Muinelo-Romay L
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32098121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
    Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
    Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.
    Giannopoulou L; Zavridou M; Kasimir-Bauer S; Lianidou ES
    Transl Res; 2019 Mar; 205():77-91. PubMed ID: 30391474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of liquid biopsy in endometrial carcinoma.
    Shen Y; Shi R; Zhao R; Wang H
    Med Oncol; 2023 Feb; 40(3):92. PubMed ID: 36757457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?
    Yu M; Zhu Y; Teng L; Cui J; Su Y
    J Oncol; 2021; 2021():6627241. PubMed ID: 33936202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A headlight on liquid biopsies: a challenging tool for breast cancer management.
    Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
    Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine.
    Adhit KK; Wanjari A; Menon S; K S
    Cureus; 2023 Dec; 15(12):e50176. PubMed ID: 38192931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer.
    Heidrich I; Abdalla TSA; Reeh M; Pantel K
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced liquid biopsy technologies for circulating biomarker detection.
    Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
    J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.
    Openshaw MR; McVeigh TP
    Front Digit Health; 2020; 2():573010. PubMed ID: 34713045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.